Insider buying last 90 days
No open-market insider purchases were filed for RYTM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Rhythm Pharmaceuticals has been dominated this week by takeover speculation, with reports that AstraZeneca made an approximately $10 billion offer to acquire the company, valued at up to $134 per share including milestone payments, and initial reports of a $124-a-share bid. Shares jumped 28% on the news, and subsequent reports of a second bidder, speculated to be a large pharmaceutical company, added a further 4.2% move. Alongside the deal talk, JP Morgan maintained an Overweight rating while trimming its target to $142 from $145, and Guggenheim maintained Buy while raising its target to $147 from $143. A separate commentary flagged the stock's price-to-sales ratio of 27.7x as stretched following a new $750 million term loan and an amended license for bivamelagon.
The stock closed at $113.94, up 1.5% on the day, sitting above both its 50-day average of $96.29 and 200-day average of $97.06, with a one-month return of 25.5% and a six-month return of 30.4%. The GekkoIndex reads 41.1, placing it in the Distribution zone, down 15.7 over the past five readings. Price sits just 0.1% above Gekko Fair Value of $113.81.
The next earnings date is 25 February 2027, 107 days out, beyond a typical 20-trading-day swing window. Over the last 30 days there has been 1 unusual options signal, with call premium of $465,115 against no put premium. One billionaire holder is recorded. Seasonally, the next 20 trading days have averaged +5.7% over 5 years, rising in 3 of them. Analyst consensus stands at 13 buy, 1 hold, 0 sell, with a consensus target of $140.29.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Rhythm Pharmaceuticals scores 3 supportive, 3 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive3 mixed0 headwinds
Averages disagree
Close $115.02 sits between the 50-day ($96.88) and 200-day ($97.24) averages, or the averages disagree.
See the chart46.7, Neutral
Reading 46.7 is in the Neutral zone.
See the GekkoIndex0.7% above
Price is within 5% of Gekko Fair Value (0.7% above).
See fair valueLeans bullish
Last 30 days: 2 unusual options signals.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings+3.7% on average
From this point in the calendar, the next 20 trading days averaged +3.7% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Rhythm Pharmaceuticals closed at $115.02 on Nov 13, 2026, +17.5% over the past year, inside a 52-week range of $74.50 to $122.20.
Use the left and right arrow keys to read daily values.
Put RYTM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Rhythm Pharmaceuticals works on medicines for rare genetic disorders that lead to obesity, combining research, development and the sale of approved treatments. Its main product, IMCIVREE, acts on the melanocortin-4 receptor pathway and is used for obesity linked to POMC, PCSK1 or LEPR deficiencies, as well as for patients with Bardet-Biedl and Alström syndromes. This treatment forms the core of what the company is recognized for in the market.
Beyond its marketed therapy, the company is studying the same active compound, setmelanotide, in Phase II trials aimed at additional conditions, including heterozygous POMC or LEPR deficiency, SRC1 and SH2B1 deficiencies, MC4 receptor deficiency, and obesity tied to Smith-Magenis syndrome and related POMC epigenetic disorders. It also participates in a collaborative research arrangement with the Clinical Registry Investigating Bardet-Biedl Syndrome, connecting its pipeline work to patients affected by these conditions.
The company is based in Boston, Massachusetts, and traces its founding to 2008, having operated originally under the name Rhythm Metabolic before adopting its current name in 2015. Its shares are listed on the NASDAQ under the ticker RYTM.
Rhythm Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 46.7, in the Neutral zone, up 3.6 points over five sessions.
Up 3.6 points over five sessions, from the Distribution zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 16 | +0.3% | +4.7% | ||
| Accumulation | 219 | +1.8% | +3.1% | ||
| Neutral (current zone) | 416 | +0.7% | +3.4% | ||
| Distribution | 44 | −1.2% | −4.3% | ||
| Selling | 7 | Too few readings yet | |||
Average RYTM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Rhythm Pharmaceuticals trades 0.7% above Gekko Fair Value of $114.18, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Rhythm Pharmaceuticals shares are worth, recalculated every trading day.
$114.18
Gekko Fair Value, Nov 14, 2026
0.7% above fair value · About fair value
At the end of Aug 2026 the price was 18.0% below the estimate.
No open-market insider purchases were filed for Rhythm Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for RYTM in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in RYTM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
2signals, 100% of the flagged premium in calls.
Latest: Bullish flow on Nov 14, $403K in unusual premium.
1of the funds Gekko tracks holds RYTM.
Rhythm Pharmaceuticals reports on Feb 25, 2027, before the open (102 days away), and beat the EPS estimate in 4 of its last 8 reports.
Feb 25, 2027
Expected before the open, 102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 3, 2026 | −$0.61 est −$0.71 | $92.13M est $85.57M | +18.5% |
| Aug 4, 2026 | −$0.73 est −$0.81 | $71.26M est $67.66M | +7.7% |
| May 5, 2026 | −$0.83 est −$0.86 | $60.11M est $55.78M | +12.9% |
| Feb 26, 2026 | −$0.73 est −$0.79 | $57.25M est $56.21M | −6.5% |
| Nov 4, 2025 | −$0.82 est −$0.72 | $51.30M est $55.98M | −12.5% |
| Aug 5, 2025 | −$0.75 est −$0.66 | $48.50M est $51.33M | −0.3% |
| May 7, 2025 | −$0.81 est −$0.69 | $32.70M est $43.28M | −3.2% |
| Feb 26, 2025 | −$0.72 est −$0.69 | $41.83M est $38.48M | +3.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Rhythm Pharmaceuticals is $140.12, +21.8% from the last close, from 14 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 14 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 5 | Canaccord Genuity | $168 | +46.1% |
| Nov 5 | Citi | $143 | +24.3% |
| Nov 4 | Citizens JMP | $166 | +44.3% |
| Nov 4 | Morgan Stanley | $146 | +26.9% |
| Nov 4 | Wells Fargo | $155 | +34.8% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Rhythm Pharmaceuticals averaged +3.7% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −6.4% | 2 of 5 |
| Next 10 trading days | −5.5% | 2 of 5 |
| Next 15 trading days | −1.0% | 3 of 5 |
| Next 20 trading days | +3.7% | 3 of 5 |
| Next 30 trading days | +7.0% | 3 of 5 |
For scale, RYTM’s typical 20-trading-day move in either direction is about 10.3%.
Rhythm Pharmaceuticals’s market cap is $7.97B and revenue of $280.7M over the last twelve months.
Coverage of Rhythm Pharmaceuticals this week reads positive: 8 positive, 1 neutral and 1 negative headlines.
Rhythm Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Rhythm Pharmaceuticals’s market cap is $7.97B at the Nov 13, 2026 close of $115.02, with 69.33M shares outstanding.
The consensus analyst 12-month price target for Rhythm Pharmaceuticals is $140.12, +21.8% from the last close. Of the 14 firms that rated the stock in the last 90 days, 13 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Rhythm Pharmaceuticals is about fair value: the Nov 13, 2026 close of $115.02 is 0.7% above Gekko Fair Value of $114.18. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Rhythm Pharmaceuticals is expected to report on Feb 25, 2027, before the market opens (102 days away). Analysts expect earnings of −$2.59 per share on revenue of $109.6M. Rhythm Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 8.2% on average across the report.
Rhythm Pharmaceuticals’s 52-week high is $122.20 and its 52-week low is $74.50; it closed at $115.02 on Nov 13, 2026, +17.5% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 3 as mixed (trend, gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in Rhythm Pharmaceuticals over the last 30 days, with $868K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 14, 2026 with $403K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.